Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
Ontology highlight
ABSTRACT: Heart failure remains a major concern across the globe as life expectancies and delivery of health care continue to improve. There has been a dearth of new developments in heart failure therapies in the last decade until last year, with the release of the results from the PARADIGM-HF Trial heralding the arrival of a promising new class of drug, ie, the angiotensin receptor-neprilysin inhibitor. In this review, we discuss the evolution of our incremental understanding of the neurohormonal mechanisms involved in the pathophysiology of heart failure, which has led to our success in modulating its various pathways. We start by examining the renin-angiotensin-aldosterone system, followed by the challenges of modulating the natriuretic peptide system. We then delve deeper into the pharmacology a
SUBMITTER: Singh JS
PROVIDER: S-EPMC4459540 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
ACCESS DATA